AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 FEB 14 - (NewsRx.com & NewsRx.net) --
- Sonia Nichols, staff medical writer -- Tiny microspheres embedded with hepatitis B surface antigen (HBsAg) may comprise the next generation of drug delivery systems for hepatitis B vaccines, if the latest research being developed in bioengineering labs pans out.
Several research institutions have already delved into the use of these microspheres as adjuvant drug delivery mechanisms for a number of pharmaceuticals. One of the latest studies, performed in the Department of Biotechnological Engineering at Ben Gurion University of Negev, has tested the use of these HBsAg entrapped microscopic orbs on mice.
The group used two sizes of microencapsulated liposome systems (MELs) in their experiments; some were coated with 214 kDa alginate-poly(L-lysine) (PLL) and others with 25 kDa PLL. Inside these small spheres were liposome entrapped particles of HBsAg.
M. Machluf and colleagues observed that MEL-214 was much better at releasing the HBsAG liposome than was MEL-25. "Concomitantly, the specific anti-HBsAg titers in mice receiving HBsAg in MELs-214 were higher than those induced by MELs-25," they said.
Furthermore, MELs-214 did a better of job of eliciting an immune response than more traditional ...
Source: HighBeam Research, Mice Inoculated with Hepatitis B Tagged Microspheres Show Good Immune...